Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Robert O Dillman; Edward McClay; Thomas Amatruda; George Semeniuk; Clark Haskins; Robert Weber; David Burtzo; Carol DePriest; Denysha Carbonell; Andrew Cornforth

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

【24h】

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

机译：树突状细胞疫苗相对于肿瘤细胞疫苗的优越性：利用自体黑素瘤肿瘤细胞系抗原的患者特异性疫苗的MACVAC随机II期临床试验中的分层亚群存活

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer》 |2015年第s2期|共页
作者
Robert O Dillman; Edward McClay; Thomas Amatruda; George Semeniuk; Clark Haskins; Robert Weber; David Burtzo; Carol DePriest; Denysha Carbonell; Andrew Cornforth;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. [J] . Dillman RO, Selvan SR, Schiltz PM Cancer biotherapy and radiopharmaceuticals . 2009,第3期

机译：在转移性黑素瘤患者中，树突状细胞负载自更新的，增殖的自体肿瘤细胞作为患者特异性抗肿瘤疫苗的抗原的II期试验：最终报告。
2. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. [J] . Dillman R, Selvan S, Schiltz P, Cancer biotherapy and radiopharmaceuticals . 2004,第5期

机译：黑色素瘤患者特异性疫苗增殖自体肿瘤细胞，树突状细胞和GM-CSF的I / II期试验：计划中的中期分析。
3. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. [J] . Dillman RO, DePriest C, DeLeon C, Cancer biotherapy and radiopharmaceuticals . 2007,第3期

机译：来自自体肿瘤细胞系的患者特异性疫苗作为主动特异性免疫疗法：转移性黑素瘤患者I / II探索性试验的结果。
4. CD40-ACTIVATED B (CD40-B) CELLS LOADED WITH AUTOLOGOUS TUMOR RNA AS A NOVEL ANTIGEN-PRESENTING CELL VACCINE FOR CANINE LYMPHOMA [C] . Amy LaBlanc, Erika L Krick, Beth Overley, Annual conference of the Veterinary Cancer Society . 2008

机译：CD40-活化的B（CD40-B）用自体肿瘤RNA负载，作为犬淋巴瘤的新型抗原呈递细胞疫苗
5. Potentiation of the immune response with aluminum-containing adjuvants: I. Distribution of adsorbed antigen in mono-valent and combination vaccines; II. Role of antigen adsorption in antigen internalization by dendritic cells. [D] . Morefield, Garry Lee, Jr. 2003

机译：含铝佐剂增强免疫应答：I.单价和组合疫苗中吸附抗原的分布；二。抗原吸附在树突状细胞的抗原内在化中的作用。
6. Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines [O] . Robert O Dillman, Edward McClay, Thomas Amatruda, 2015

机译：树突状细胞疫苗相对于肿瘤细胞疫苗的优越性：利用自体黑素瘤肿瘤细胞系抗原的患者特异性疫苗的MACVAC随机II期临床试验中的分层亚群存活
7. Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines [O] . 2015

机译：树突状细胞疫苗相对于肿瘤细胞疫苗的优越性：利用自体黑素瘤肿瘤细胞系抗原的患者特异性疫苗的MACVAC随机II期临床试验中的分层亚群存活

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

著录项

相似文献

相关主题

期刊订阅